Zogenix fell 23 percent to $3.51 at 4 p.m. New York time, its biggest one-day move since December 2012. The stock had doubled from when the drug was approved through yesterday. Purdue plans to ask the FDA for a …
Roger Hawley, chief executive officer of Zogenix, stated, "During the first quarter we successfully ... Company's outstanding warrants driven primarily by changes in the Company's stock price. Net loss for the first quarter …
SAN DIEGO, June 18, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, …
SHARE ACTION: Zogenix Inc.'s stock fell $1.10, or 46.6 percent, to $1.26 in afternoon trading. Earlier in the session the stock dropped to $1.25, its lowest level since the shares went public in November 2010.
Avramut ... Zogenix. Consultant: Allergan, GSK, Helsinn, MAP, Merck, Nautilus, NuPathe, Zogenix. Speakers Bureau: Allergan, GSK, Merck, Nautilus, Zogenix. Advisors Board: Allergan, GSK, Merck, MAP, Nautilus, …
John Wiley & Sons
Zogenix Inc. (NASDAQ:ZGNX) had a big day on Wednesday ... The OBV has a new high for the year. Look for this stock to reach up to 21.65, and if it takes that out, look for it to run up to 25.00.
The FDA missed a March 1 deadline on whether to approve Zohydro because it needed more time to review information about the drug, according to a statement issued by Zogenix. The stock price for Zogenix surged …
Once the deal closes, Pernix agreed to pay Zogenix $30 million in cash upfront, along with $20 million in common stock, and to provide a $50 million short-term promissory note. Zogenix said it agreed to support …
Sells
He says this suit could crash the stock. He wants me to buy 20,000 shares of Zogenix with the money from the sale of Merck. Zogenix is a small specialty drug company. His research department believes that it has a …
Drug developer Zogenix Inc. (Nasdaq: ZGNX) plans to sell its common stock to raise $56 million after the company’s accountant raised concerns about Zogenix’s ability to continue without liquidation. The San Diego …